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If We Could Only Predict the Future*Vera Bittner, MD, MSPHSEE PAGE 2699S tatins are effective in the primary and second-ary prevention of coronary heart disease andstroke. Although many would agree that pri-
mary prevention of atherosclerotic cardiovascular
disease (ASCVD) is preferable to secondary preven-
tion, no consensus exists on how to best identify indi-
viduals at risk for the disease, when to commence
screening and risk assessment, at what age to start
(or stop) treatment, how to treat, and how intensively
to treat. The 2013 American College of Cardiology/
American Heart Association (ACC/AHA) cholesterol
guidelines concluded that net beneﬁt was sufﬁcient
to recommend statin treatment for patients with
primary low-density lipoprotein (LDL) cholesterol
elevations $190 mg/dl and for those age 40 to 75
years with an LDL cholesterol level between 70 and
189 mg/dl and $7.5% 10-year ASCVD risk derived
from the pooled cohort risk equation (1). The
guideline authors further emphasized that risk strati-
ﬁcation should be followed by a clinician–patient
discussion and shared decision-making. Although
several investigator groups have reported good
calibration and case discrimination with the pooled
cohort risk equation, others found overestimation of
ASCVD risk.
Concerns regarding potential overtreatment thus
persist, especially among older subjects whose
primary determinant of risk in the equation is age.*Editorials published in the Journal of the American College of Cardiology
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Amgen and Eli Lilly.Alternate approaches to identifying subjects likely to
beneﬁt from primary prevention with statins have
thus been proposed. Ridker and Wilson (2) described
an approach using entry criteria from primary pre-
vention statin trials and, given null results, limiting
statin therapy in subjects with heart failure or
undergoing hemodialysis. More recently, Ridker et al.
(3) proposed a hybrid approach using both trial entry
criteria and global risk prediction. How does the
practicing clinician choose among these approaches?In this issue of the Journal, Mortensen et al. (4)
describe a head-to-head comparison of the 2013
ACC/AHA guideline approach, a trial-based approach,
and a hybrid approach. They applied these ap-
proaches to the Copenhagen General Population
Study, a contemporary population-based cohort of
Danish men and women. After excluding patients
with diabetes, ASCVD, statin use, or missing infor-
mation at baseline, as well as those patients who were
outside the age range of 40 to 75 years (thus including
only the age range recommended in the ACC/AHA
guidelines), the authors followed up 37,892 patients
prospectively for 5 years for the occurrence of “hard”
ASVCD events. Statin eligibility varied greatly among
the 3 approaches: 42% with the 2013 ACC/AHA
approach, 56% with the trial-based approach, and
21% with the hybrid approach. Importantly, these
approaches identiﬁed different individuals in the
population, a phenomenon more apparent in women
than in men.
Using methods identical to those of Muntner et al.
(5), Mortensen et al. (4) found that the 2013 ACC/AHA
algorithm was well calibrated in the 7.5% risk range in
this population. The predicted event rate (per 1,000
patient-years) was highest with the hybrid approach
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2711(11.2), intermediate with the 2013 ACC/AHA algorithm
(9.8), and lowest with the trial-based approach (6.8).
Discrimination was moderate with all approaches,
highest with the 2013 ACC/AHA approach, interme-
diate with the hybrid approach, and lowest with the
trial-based approach (area under the receiver-
operating characteristic curves of 0.676, 0.613, and
0.572, respectively). Compared with the 2013 ACC/
AHA approach, the trial-based and hybrid approaches
had negative net reclassiﬁcation indexes. The authors
thus concluded that the guidelines-recommended
approach will prevent more ASCVD events and,
compared with the trial-based approach, will achieve
this goal by treating fewer people.
Do these results resolve the dilemma for the prac-
ticing clinician on whom to treat and how to treat?
Among the 3 options, the 2013 ACC/AHA guidelines
approach seemed to be best for identifying subjects
destined to have a future event (4). However, is this
approach necessarily best at identifying subjects at
risk who will beneﬁt from treatment? In clinical trials
of lipid-lowering therapy, relative risk reductions are
generally in the 30% range (6). In a trial-based strat-
egy, there is an inherent assumption that subjects
who meet the same entry characteristics as subjects
enrolled in the trials would experience this same
relative risk reduction, assuming similar adherence to
therapy. However, the trial-based strategy does not
try to match exclusion criteria, thus identifying a
substantially larger group of subjects than would
have been eligible to participate in the trials. In
addition, each decision about trial participation is
based not only on inclusion and exclusion criteria but
also on unmeasured patient and investigator charac-
teristics that would be impossible to match; these
characteristics, however, could exert a major impact
on ultimate treatment beneﬁt.
For a risk-based approach, we have no prospective
data on expected beneﬁt from treatment and have to
extrapolate that the beneﬁt would be similar to that
observed in the clinical trials. Some argue that risk
driven by age and nonlipid risk factors would be
less likely to beneﬁt from lipid-lowering therapy.
Others might argue that lipid-lowering therapy will be
effective: after all, subjects with lifelong lower LDL
cholesterol levels through proprotein convertase
subtilisin/kexin type 9 (PCSK9) mutations seem to be
protected from ASCVD even in the presence of major
nonlipid risk factors (7). The answer could only come
from a randomized trial, but such a trial would be
complex and expensive and is unlikely to be funded.
All 3 approaches suffer from the limited data we
have on nonwhite subjects. The 2013 ACC/AHA
calculator provides estimates for white and blacksubjects but does not have speciﬁc estimates for other
ethnicities. Trial and hybrid approaches are inher-
ently hampered by the types of participants in the
trials and, potentially, by the limited applicability of
trials conducted in speciﬁc populations in other
geographic regions, risk environments, or ethnicities.
Last, but not least: what about the 8% of subjects
not identiﬁed by any of the approaches but who
nevertheless experienced events? What did we miss?
As one would expect, these subjects had a global
risk below the threshold and did not meet typical
trial entry criteria. However, one intriguing
observation emerges from Online Tables 2 to 4
accompanying Mortensen et al. (4): such subjects had
substantially higher lipoprotein(a) (Lp[a]) levels.
Should we adopt Lp(a) more widely as a marker to
identify subjects at risk and use Lp(a) levels as a
treatment criterion? Or should we go further and
make Lp(a) a treatment target (8)? Clearly, additional
research is needed in this area, and ongoing trials
with PCSK9 inhibitors will provide important insights
in the near future.
So what do I tell my primary prevention patient in
the clinic tomorrow? Quantiﬁcation of risk is just a
ﬁrst step. For now, the 2013 ACC/AHA risk calculator
is our best tool to accomplish this goal and, in the
absence of contraindications or patient wishes, we
should treat those who fall into the primary preven-
tion statin beneﬁt groups. However, it is worth
remembering that, in the absence of end-stage renal
disease and heart failure, we have no data conﬁrming
that subjects who fall outside the age and lipid
thresholds that deﬁne the statin beneﬁt groups would
not beneﬁt from treatment. A thorough evaluation of
each subject’s circumstances, a detailed clinician–
patient discussion, and shared decision making are
critical. Let us remember, too, that an exclusive
“lipocentric approach” to ASCVD risk reduction be-
gets large residual risk, as documented by the results
of our lipid-lowering clinical trials (6).
Atherosclerosis is a multifactorial disease and
requires a multifactorial approach with smoking
cessation, dietary modiﬁcation and weight manage-
ment, regular physical activity, attention to psycho-
social risk factors, and pharmacological therapy of
lipid and nonlipid risk factors. Comprehensive risk
factor control is associated with improved prognosis,
and our challenge is to develop care models that will
allow us to achieve such control.
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